Distinctive deregulation of miR-27a and miR-27b in relapsing remitting multiple sclerosis
Authors
Abstract:
Introduction: Previous studies have proposed that microRNAs (miRNAs) expression might be responsible for immunological features associated with multiple sclerosis (MS) pathogenesis. We aimed to elucidate the alternation in miR-27a and miR-27b expression in relapsing-remitting multiple sclerosis (RRMS) patients compared to the healthy subjects. Materials and methods: In this study, the expression levels of miR-27a and miR-27b were evaluated in peripheral blood samples of 60 RRMS patients (30 recurrence patients and 30 patients two months after relapse) and 30 healthy subjects by quantitative real-time PCR. Results: The findings indicated that the expression of miR-27a was significantly decreased in recurring patients (P<0.0001) and two months after relapse patients (P<0.003) in comparison with healthy subjects. Moreover, miR-27b showed down regulation in recurring patients (P<0.001) and two months after relapse patients (P<0.002). Conclusion: The results demonstrated an association between expression of miRNAs studied and RRMS disease during recurrence and two months after relapse. However, further research is warranted to confirm observed associations.
similar resources
Altered Expression of Circulating miR-377 and miR-98 in Relapsing-remitting Multiple Sclerosis
Background and Aims: Multiple sclerosis (MS) has been assumed to be a complex and indecipherable disease, and poorly understood with regard to etiology which is characterized by relapses and remissions. The expression of microRNAs (miRNAs) is known to be associated with the regulation of immune responses. Recently, investigations have reported that miRNA expression profiles in blood cells becom...
full textIncreased Expression of miR-202-3p in Patients with Relapsing-Remitting Multiple Sclerosis
Background and objectives: One of the latest studies in the genetics field is the evaluation of role of micro-RNAs as a biomarker for diagnosis of multiple sclerosis (MS), which is a demyelinating disease of the central nervous system (CNS) and emerges in the form of numerous small and large plaques in white matter in the brain and spinal cord. This disease could be associated with several comp...
full textP120: Efficacy and Safety of Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disorder of central nervous system. This demyelinating disease affects more than 2.3 million people world wild. Most of patients are young adult. The most common type of MS is relapsing remitting multiple sclerosis (RRMS). However there is no cure, available modifying therapies has revolutionized the care of patients with RRMS. Interferon (IFN) be...
full textSafety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of D...
full textComparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis
Background: The present study aimed to compare the clinical efficacy and safety profile of Ziferon and Betaferon. Objectives: In total, 41 consecutive patients with relapsing forms of Multiple Sclerosis (MS) were selected from the MS outpatient clinic affiliated to Tehran University of Medical Sciences. The patients were randomly assigned into two groups. Methods: Each group either received Z...
full textInterferons in relapsing remitting multiple sclerosis.
BACKGROUND Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS. SEARCH STRATEGY Of 208 articles identified by a predefined ...
full textMy Resources
Journal title
volume 7 issue 2
pages 1- 6
publication date 2020-03
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023